MCH ADVISORY RESEARCH
Research hub

The research library

Every note in one place — search by ticker, company or theme, and filter by sector, industry, rating or type.

Browse

By sector

Communication Services 21Consumer Discretionary 101Consumer Staples 48Energy 37Equity Research 6Financials 136Health Care 85Industrials 161Information Technology 108Materials 51Real Estate 59Utilities 45
Companies A–Z →Industries →Themes →Full index →
Explore

Coverage

865 reports
Equity Research

Agilent Technologies Inc (A)

SELL. 12-month probability-weighted target $133 (-13% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

AEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Alcoa Corp (AA)

HOLD. 12-month probability-weighted target $49 (+0% vs spot). P/E Multiple explains 47% of Monte Carlo outcome variance.

AAEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

American Airlines Group (AAL)

HOLD. 12-month probability-weighted target $15 (+10% vs spot). Gross Margin explains 55% of Monte Carlo outcome variance.

AALEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

AAON Inc (AAON)

BUY. 12-month probability-weighted target $107 (+41% vs spot). Gross Margin explains 54% of Monte Carlo outcome variance.

AAONEquity ResearchMonte Carlo
25 August 2026Rating: BUY
Equity Research

Apple Inc. (AAPL)

SELL. 12-month probability-weighted target $271 (-13% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.

AAPLEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Single-name · Consumer Tech

AAPL: a real growth inflection — but the stock has already paid for it

iPhone +22%, China +30%, Services at a record. Real inflection — but triangulated fair value (~$279) sits just below spot. HOLD.

AAPLAppleConsumer TechAI
15 June 2026AAPL
Equity Research

AbbVie Inc (ABBV)

HOLD. 12-month probability-weighted target $236 (-11% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.

ABBVEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Airbnb Inc (ABNB)

SELL. 12-month probability-weighted target $142 (-25% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.

ABNBEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Abbott Laboratories (ABT)

SELL. 12-month probability-weighted target $93 (-20% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

ABTEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Arch Capital Group Ltd. (ACGL)

HOLD. 12-month probability-weighted target $97 (-3% vs spot). P/E Multiple explains 58% of Monte Carlo outcome variance.

ACGLEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Albertsons Companies (ACI)

BUY. 12-month probability-weighted target $22 (+93% vs spot). Gross Margin explains 78% of Monte Carlo outcome variance.

ACIEquity ResearchMonte Carlo
2 August 2026Rating: BUY
Equity Research

Aecom Technology Corporation (ACM)

BUY. 12-month probability-weighted target $81 (+24% vs spot). Gross Margin explains 61% of Monte Carlo outcome variance.

ACMEquity ResearchMonte Carlo
25 August 2026Rating: BUY
Equity Research

Accenture plc (ACN)

SELL. 12-month probability-weighted target $119 (-36% vs spot). Gross Margin explains 51% of Monte Carlo outcome variance.

ACNEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Adobe Systems Incorporated (ADBE)

SELL. 12-month probability-weighted target $202 (-27% vs spot). P/E Multiple explains 89% of Monte Carlo outcome variance.

ADBEEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Agree Realty Corporation (ADC)

HOLD. 12-month probability-weighted target $82 (+10% vs spot). P/E Multiple explains 91% of Monte Carlo outcome variance.

ADCEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Analog Devices Inc (ADI)

HOLD. 12-month probability-weighted target $380 (+2% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.

ADIEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Archer-Daniels-Midland Company (ADM)

HOLD. 12-month probability-weighted target $78 (+0% vs spot). Gross Margin explains 68% of Monte Carlo outcome variance.

ADMEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Automatic Data Processing Inc (ADP)

SELL. 12-month probability-weighted target $222 (-22% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.

ADPEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Autodesk Inc (ADSK)

SELL. 12-month probability-weighted target $195 (-23% vs spot). P/E Multiple explains 91% of Monte Carlo outcome variance.

ADSKEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Ameren Corp (AEE)

HOLD. 12-month probability-weighted target $117 (+9% vs spot). P/E Multiple explains 53% of Monte Carlo outcome variance.

AEEEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Advanced Energy Industries Inc (AEIS)

HOLD. 12-month probability-weighted target $280 (+2% vs spot). P/E Multiple explains 62% of Monte Carlo outcome variance.

AEISEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

American Electric Power Co Inc (AEP)

HOLD. 12-month probability-weighted target $136 (+11% vs spot). Gross Margin explains 52% of Monte Carlo outcome variance.

AEPEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

The AES Corporation (AES)

At $14.82 (30 July 2026) AES trades on roughly 6.4 times forward earnings against a merchant-utility peer median near 21 times. The market is pricing a leveraged builder whose $29.4B of net debt, not its contracted…

AESEquity ResearchMonte Carlo
30 July 2026Rating: N/A
Equity Research

American Financial Group, Inc. (AFG)

HOLD. 12-month probability-weighted target $148 (+3% vs spot). Gross Margin explains 48% of Monte Carlo outcome variance.

AFGEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Aflac Incorporated (AFL)

HOLD. 12-month probability-weighted target $122 (+3% vs spot). P/E Multiple explains 70% of Monte Carlo outcome variance.

AFLEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

AGCO Corporation (AGCO)

HOLD. 12-month probability-weighted target $111 (+1% vs spot). Gross Margin explains 57% of Monte Carlo outcome variance.

AGCOEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

American Healthcare REIT, Inc. (AHR)

SELL. 12-month probability-weighted target $47 (-16% vs spot). Gross Margin explains 56% of Monte Carlo outcome variance.

AHREquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

American International Group Inc (AIG)

HOLD. 12-month probability-weighted target $72 (-7% vs spot). P/E Multiple explains 56% of Monte Carlo outcome variance.

AIGEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Applied Industrial Technologies (AIT)

HOLD. 12-month probability-weighted target $339 (+0% vs spot). Gross Margin explains 60% of Monte Carlo outcome variance.

AITEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Assurant, Inc. (AIZ)

HOLD. 12-month probability-weighted target $259 (-10% vs spot). Gross Margin explains 61% of Monte Carlo outcome variance.

AIZEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Arthur J Gallagher & Co (AJG)

SELL. 12-month probability-weighted target $219 (-19% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

AJGEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Akamai Technologies Inc (AKAM)

HOLD. 12-month probability-weighted target $114 (+8% vs spot). P/E Multiple explains 74% of Monte Carlo outcome variance.

AKAMEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Albemarle Corp (ALB)

HOLD. 12-month probability-weighted target $141 (-1% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.

ALBEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Allegro Microsystems Inc (ALGM)

BUY. 12-month probability-weighted target $47 (+31% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

ALGMEquity ResearchMonte Carlo
25 August 2026Rating: BUY
Equity Research

Align Technology Inc (ALGN)

HOLD. 12-month probability-weighted target $169 (+6% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

ALGNEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Alaska Air Group Inc (ALK)

HOLD. 12-month probability-weighted target $46 (+10% vs spot). Gross Margin explains 52% of Monte Carlo outcome variance.

ALKEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

The Allstate Corporation (ALL)

SELL. 12-month probability-weighted target $233 (-10% vs spot). Gross Margin explains 63% of Monte Carlo outcome variance.

ALLEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Allegion PLC (ALLE)

SELL. 12-month probability-weighted target $136 (-17% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.

ALLEEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Ally Financial Inc (ALLY)

HOLD. 12-month probability-weighted target $44 (+3% vs spot). P/E Multiple explains 87% of Monte Carlo outcome variance.

ALLYEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Allison Transmission Holdings Inc (ALSN)

SELL. 12-month probability-weighted target $110 (-16% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.

ALSNEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Autoliv Inc (ALV)

HOLD. 12-month probability-weighted target $115 (-7% vs spot). Gross Margin explains 58% of Monte Carlo outcome variance.

ALVEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Antero Midstream Partners LP (AM)

HOLD. 12-month probability-weighted target $24 (+7% vs spot). P/E Multiple explains 89% of Monte Carlo outcome variance.

AMEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Amcor PLC (AMCR)

SELL. 12-month probability-weighted target $41 (-14% vs spot). Gross Margin explains 66% of Monte Carlo outcome variance.

AMCREquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Ametek Inc (AME)

HOLD. 12-month probability-weighted target $241 (+0% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

AMEEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Affiliated Managers Group, Inc. (AMG)

SELL. 12-month probability-weighted target $282 (-21% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.

AMGEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Amgen Inc (AMGN)

SELL. 12-month probability-weighted target $355 (-20% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.

AMGNEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

American Homes 4 Rent (AMH)

HOLD. 12-month probability-weighted target $33 (-5% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.

AMHEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Amkor Technology Inc (AMKR)

BUY. 12-month probability-weighted target $62 (+30% vs spot). Gross Margin explains 56% of Monte Carlo outcome variance.

AMKREquity ResearchMonte Carlo
25 August 2026Rating: BUY
Equity Research

Ameriprise Financial Inc (AMP)

SELL. 12-month probability-weighted target $423 (-25% vs spot). P/E Multiple explains 67% of Monte Carlo outcome variance.

AMPEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

American Tower Corp (AMT)

HOLD. 12-month probability-weighted target $174 (-2% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.

AMTEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Amazon.com (AMZN)

HOLD. 12-month probability-weighted target $247 (-6% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

AMZNEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

AutoNation Inc (AN)

HOLD. 12-month probability-weighted target $196 (+1% vs spot). Gross Margin explains 55% of Monte Carlo outcome variance.

ANEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Arista Networks (ANET)

SELL. 12-month probability-weighted target $157 (-16% vs spot). P/E Multiple explains 87% of Monte Carlo outcome variance.

ANETEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Abercrombie & Fitch Company (ANF)

HOLD. 12-month probability-weighted target $106 (-5% vs spot). Gross Margin explains 63% of Monte Carlo outcome variance.

ANFEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Aon PLC (AON)

HOLD. 12-month probability-weighted target $325 (-9% vs spot). P/E Multiple explains 70% of Monte Carlo outcome variance.

AONEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Smith AO Corporation (AOS)

HOLD. 12-month probability-weighted target $61 (-3% vs spot). P/E Multiple explains 50% of Monte Carlo outcome variance.

AOSEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

APA Corporation (APA)

HOLD. 12-month probability-weighted target $40 (-7% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

APAEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Air Products and Chemicals Inc (APD)

HOLD. 12-month probability-weighted target $284 (-7% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

APDEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Api Group Corp (APG)

HOLD. 12-month probability-weighted target $39 (-4% vs spot). Gross Margin explains 49% of Monte Carlo outcome variance.

APGEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Amphenol Corporation (APH)

HOLD. 12-month probability-weighted target $160 (+3% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.

APHEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Coverage

Names not covered, and why

31 names in the S&P 900 universe carry no published report. Each is a recorded decision, not an oversight: the engine refuses to model on corrupt vendor data or to invent assumptions a valuation lens cannot source. A name joins coverage when its recorded blocker clears. A further 3 are dual-class listings covered via their primary share class.

The full list (34)
TickerCompanyRecorded reason
APPFAppFolioAppFolio — hyper-growth vertical SaaS at ~128x fwd P/E; software PE band clamps target to 77 vs 179 spot (−57%, below the 52-week low) while Street is +25%. CAVA-style lens break — needs a growth-appropriate multiple.
ARWRArrowhead PharmaceuticalsArrowhead Pharma — clinical/early-commercial RNAi biotech; de-minimis fwd EPS $0.64 → 111x P/E, model −70% vs Street +34%. EPS×PE meaningless on emerging biotech earnings.
BABoeingnear-zero forward EPS (P/E ~833, 737-MAX/quality recovery); the EPS×PE lens cannot represent the earnings normalization — manual/turnaround treatment
BF.BBrown–Formandual-class (Brown-Forman); AV dot-ticker fetch failed — verify/author manually
BHFBrighthouse FinancialAnnuity/life insurer — negative ROE + opaque embedded value; trades 0.68x book for structural reasons EPS×PE/P-B cannot capture (model implied +98%). Needs embedded-value/EV treatment.
BTSGBrightSpring Health ServicesBrightSpring Health — PE-backed levered pharmacy/home-health rollup; heavy interest/D&A crush GAAP EPS → 38.8x P/E, model −43% vs Street +8%. EV/EBITDA candidate (EPS×PE wrong lens for a levered rollup).
CAVACava GroupCAVA — hyper-growth restaurant at ~125x fwd P/E; the restaurant EPS×PE archetype caps it far below the market (model −69%). Needs a growth-appropriate lens, not a normal PE.
CHRDChord EnergyChord Energy — AV fundamentals gap: OVERVIEW returned only price + 52w range (no fwd EPS / revenue / shares / margins), so no config could be authored. Data defect, not a lens issue — re-pull fundamentals before re-adding.
CHTRCharter Communicationsanomalous AV ForwardPE (3.097) — verify forward EPS before authoring
CRBGCorebridge FinancialCorebridge (AIG life spinoff) — annuity earnings the market discounts to ~4.6x P/E; EPS×PE over-values (implied +73%). Needs embedded-value treatment.
CYTKCytokineticsCytokinetics — early-commercial biotech; fwd EPS $0.67 → 118x P/E + 22% MC-EPS drift, model −71% vs Street +36%. Emerging-EPS lens break.
DOCNDigitalOceanDigitalOcean — ~106x fwd P/E; software band compresses to −48% vs Street +49% (−65% house-vs-Street gap). Hyper-PE lens break.
DUOLDuolingoDuolingo — wide 52-week range trips the price-anomaly gate (recent-IPO run); verify spot then --allow-price-anomaly.
EQHEquitable HoldingsEquitable — NEGATIVE GAAP book value per share (rate/AOCI marks); justified-P/B undefined and fwd EPS is mark-to-market noise. Needs embedded-value treatment.
FISVFiservAV revenue null (stale ticker — Fiserv renamed to FI); verify/remap before authoring
HIMSHims & Hers HealthHims & Hers — hyper-growth GLP-1 telehealth at ~59x fwd P/E; band overcompresses to −62% (Street already bearish at −13%, but the magnitude is a lens artifact). Needs a growth-appropriate lens.
KIMKimco RealtyAV cash-flow anomaly — FFO proxy (NI + D&A) computes negative for a profitable REIT; verify D&A before authoring
LYVLive Nation EntertainmentEBITDA/FCF story, minimal GAAP EPS (P/E ~476) — needs EV/EBITDA treatment
MPMP MaterialsMP Materials — rare-earth miner at breakeven; fwd EPS $0.09 → 500x P/E, model −95% vs Street +73% (a strategic-supply story earnings cannot capture). EPS×PE meaningless — EV/EBITDA or NAV lens.
MRNAModernanegative TTM gross margin (post-COVID); forward EPS reflects a pipeline recovery the EPS×PE lens cannot represent — manual/pipeline treatment
MUMicron Technologyno vendor estimates; overview fwd_eps 166.0 internally impossible (2026-08-07)
MZTIThe Marzetti CompanyMarzetti (Lancaster Colony) — premium specialty-food compounder that structurally trades ~30–36x; packaged_food band caps it → target $73 BELOW the 52-week low ($104) vs Street $159 (+45%). Premium-name lens break — needs a growth/quality-appropriate multiple.
ORAOrmat TechnologiesOrmat Technologies — premium geothermal renewable IPP that structurally trades 30–55x on its growth story; ipp_power band caps its 54.6x fwd P/E → target $49 BELOW the 52-week low ($84) vs Street $134 (+29%), P(>current) 5.5%. Premium-growth lens break — needs a growth-appropriate renewable multiple.
PENPenumbra, Inc.Penumbra — premium-growth neurovascular medtech that structurally trades 50–70x; medical_devices band caps it → −36% vs Street +14%. Structural-high-multiple lens break.
ROIVRoivant SciencesRoivant — pre-profit biotech holding co; no meaningful fwd EPS (config failed to author). No earnings lens applies.
ROKURoku, Inc.Roku — hyper-growth streaming PLATFORM mis-fit to the media_legacy archetype (built for declining legacy media); emerging EPS at 62x fwd P/E → band overcompresses to target $51 BELOW the 52-week low ($79) vs Street $158 (+10%), P(>current) 1.2%. Wrong-archetype + hyper-PE lens break — needs a growth/platform lens.
SITMSiTimeSiTime — hyper-growth MEMS timing; model −26% vs Street +51% (−51% gap). PE lens strains on a 40%+ grower — needs a growth-appropriate lens.
SNDKSandiskAV data anomaly — price × shares implies a ~$284B market cap and >70% net margin for SanDisk (both impossible); verify price/share-count before authoring
STXSeagate Technologyno vendor estimates; overview fwd_eps 36.08 internally impossible (2026-08-07)
TTMITTM TechnologiesTTM Technologies — corrupted guided EPS $23.70 (≈10x the real ~$2.5) manufactured a bogus 5.6x P/E and a fake +78% BUY; caught by the MC-implied-EPS-vs-guided drift warning (19%>10%). DATA-INTEGRITY defer — verify fwd_eps against filings before re-adding.
WBDWarner Bros. Discoverynear-zero forward EPS (P/E ~2500) — EPS×PE lens invalid; needs EV/EBITDA treatment
FOXFox Corporation (Class B)dual-class duplicate of FOXA
GOOGAlphabet Inc. (Class C)dual-class duplicate of GOOGL (already live)
NWSNews Corp (Class B)dual-class duplicate of NWSA
MCH ADVISORY SERVICES · All research · Not investment advicemchadvisoryservices.com ↗ · Research Standard v4 (decision-level) · Research OS ros-1.19.0 · US-listed · UK English